Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 in high-risk NMIBC after intravesical therapy failure
CTR20131716Phase 2Completed
- Sponsor
- Asieris Pharmaceuticals
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of APL-1202 + APL-1501 in bladder cancer, transitional cell carcinoma of the bladder (TCC), sponsored by Asieris Pharmaceuticals. Started May 2014; status: completed.
02
Drugs
APL-1202 + APL-1501
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on CTR20131716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131716.